62,264 Shares in Allakos Inc. (NASDAQ:ALLK) Acquired by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC acquired a new stake in Allakos Inc. (NASDAQ:ALLK) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 62,264 shares of the company’s stock, valued at approximately $75,000. ADAR1 Capital Management LLC owned about 0.07% of Allakos at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of ALLK. FMR LLC lifted its position in shares of Allakos by 14.6% during the 3rd quarter. FMR LLC now owns 5,370,247 shares of the company’s stock valued at $3,508,000 after buying an additional 685,623 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Allakos in the 3rd quarter valued at about $1,143,000. Geode Capital Management LLC lifted its holdings in Allakos by 8.9% during the third quarter. Geode Capital Management LLC now owns 988,171 shares of the company’s stock valued at $646,000 after purchasing an additional 80,763 shares during the last quarter. Finally, Alta Partners Management Company L.P. bought a new position in Allakos during the fourth quarter worth about $3,081,000. 84.64% of the stock is owned by institutional investors.

Allakos Stock Up 1.4 %

Shares of NASDAQ ALLK opened at $0.32 on Tuesday. The company has a market cap of $28.82 million, a P/E ratio of -0.16 and a beta of 0.62. Allakos Inc. has a 52 week low of $0.22 and a 52 week high of $1.56. The business has a 50-day simple moving average of $0.27 and a two-hundred day simple moving average of $0.74.

Analysts Set New Price Targets

ALLK has been the topic of several research reports. Piper Sandler lowered shares of Allakos from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 27th. Citizens Jmp lowered shares of Allakos from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 27th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $2.00.

Allakos Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.